However a few gastric and esophageal cancers without HER2-amplification show phosphorylation of HER3, suggesting the possibility of ligand-driven signaling or receptor cross-talk in these cancer cells (KatoIII, SNU-5, SNU-16, TE-7). This evidence concerns the gene ERBB3 and esophageal cancer.